AbbVie has treated the first subject in the Phase III CERVINO trial of ABBV-383 to treat relapsed/refractory multiple myeloma ...

Senior vice president of Novo Nordisk, Thomas Senderovitz, said that big pharma needs to have more involvement in AI ...

GlobalData has estimated Tapinarof’s sales to reach $766 million by 2030 globally for AD, subject to approval.

Gilead Sciences has reported two-year data from the Phase III ASSURE study of seladelpar in patients with primary biliary ...

mRESVIA has received FDA approval for use in adults ages 60 years and older. Credit: Momentum studio via Shutterstock. Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has received US Food ...

The overall safety data observed in the trial aligned with UPLIZNA’s known safety profile. Credit: PeopleImages.com – Yuri A / Shutterstock. Amgen has reported positive topline outcomes from the Phase ...

Moderna and MSD have announced positive results from a Phase IIb study of mRNA-4157 (V940) plus KEYTRUDA for melanoma.

Oral ganaxolone, marketed under the brand name Ztalmy, first received FDA approval to treat seizures associated with CDKL5 deficiency disorder in March 2022. Credits: Tunatura/Shutterstock.com Marinus ...

“Teliso-V is our most advanced c-Met targeted ADC in development,” said Dr. Daejin Abidoye, head of solid tumor oncology, ...

Avutometinib won orphan drug designation from the US Food and Drug Administration (FDA) in March 2024. The agency designated ...

J&J's Rybrevant is expected to generate $4bn in sales by 2030, as per GlobalData estimates.

Novo Nordisk said that via automation, AI and supportive partnerships, it believes it can reduce FPA to go live to one day. Image credit: JHVEPhoto / Shutterstock. Novo Nordisk is hoping its ...